Dextran sulfate sodium leads to chronic colitis and pathological angiogenesis in endoglin heterozygous mice

Inflammatory Bowel Diseases

Volumn 16, Issue 11, 2010, Pages 1859-1870

  Jerkic, Mirjana ^a,b   Peter, Madonna ^a,c   Ardelean, Daniela ^a   Fine, Michael ^a   Konerding, Moritz A ^d   Letarte, Michelle ^a,b,c  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

angiogenesis; endoglin; inflammation; inflammatory bowel disease; VEGF

Indexed keywords

ANGIOPOIETIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; DEXTRAN SULFATE; ENDOGLIN; EVANS BLUE; VASCULOTROPIN; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENTERITIS; HETEROZYGOSITY; INTESTINE CRYPT; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM;

ACUTE DISEASE; ANGIOPOIETINS; ANIMALS; CAPILLARY PERMEABILITY; COLITIS; COLON; DEXTRAN SULFATE; DISEASE MODELS, ANIMAL; HETEROZYGOTE; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 78249232956     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21288     Document Type: Article

References (47)

1. Pober JS, Sessa WC,. Evolving functions of endothelial cells in inflammation. Nat Rev Immunol. 2007; 7: 803-815.
2. Danese S,. Inflammation and the mucosal microcirculation in inflammatory bowel disease: the ebb and flow. Curr Opin Gastroenterol. 2007; 23: 384-389.
3. Danese S, Dejana E, Fiocchi C,. Immune regulation by microvascular endothelial cells: directing innate and adaptive immunity, coagulation, and inflammation. J Immunol. 2007; 178: 6017-6022.
4. Jackson JR, Seed MP, Kircher CH, et al. The codependence of angiogenesis and chronic inflammation. FASEB J. 1997; 11: 457-465.
5. Szekanecz Z, Koch AE,. Vascular endothelium and immune responses: implications for inflammation and angiogenesis. Rheum Dis Clin North Am. 2004; 30: 97-114.
6. Spalinger J, Patriquin H, Miron MC, et al. Doppler US in patients with Crohn disease: vessel density in the diseased bowel reflects disease activity. Radiology. 2000; 217: 787-791.
7. Maconi G, Sampietro GM, Russo A, et al. The vascularity of internal fistulae in Crohns disease: an in vivo power Doppler ultrasonography assessment. Gut. 2002; 50: 496-500.
8. Chidlow JH, Jr., Langston W, Greer JJ, et al. Differential angiogenic regulation of experimental colitis. Am J Pathol. 2006; 169: 2014-2030.
9. Scaldaferri F, Vetrano S, Sans M, et al. VEGF-A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis. Gastroenterology. 2009; 136: 585-595e585.
10. Takahashi H, Shibuya M,. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond). 2005; 109: 227-241.
11. Dvorak HF, Detmar M, Claffey KP, et al. Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation. Int Arch Allergy Immunol. 1995; 107: 233-235.
12. Lee YC,. The involvement of VEGF in endothelial permeability: a target for anti-inflammatory therapy. Curr Opin Investig Drugs. 2005; 6: 1124-1130.
13. Nagy JA, Dvorak AM, Dvorak HF,. VEGF-A and the induction of pathological angiogenesis. Annu Rev Pathol. 2007; 2: 251-275.
14. Koutroubakis IE, Xidakis C, Karmiris K, et al. Potential role of soluble angiopoietin-2 and Tie-2 in patients with inflammatory bowel disease. Eur J Clin Invest. 2006; 36: 127-132.
15. Pousa ID, Mate J, Salcedo-Mora X, et al. Role of vascular endothelial growth factor and angiopoietin systems in serum of Crohns disease patients. Inflamm Bowel Dis. 2008; 14: 61-67.
16. Yoshizaki A, Nakayama T, Naito S, et al. Expression patterns of angiopoietin-1, -2, and tie-2 receptor in ulcerative colitis support involvement of the angiopoietin/tie pathway in the progression of ulcerative colitis. Dig Dis Sci. 2009; 54: 2094-2099.
17. Shull MM, Ormsby I, Kier AB, et al. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature. 1992; 359: 693-699.
18. Kulkarni AB, Karlsson S,. Transforming growth factor-β1 knockout mice. A mutation in one cytokine gene causes a dramatic inflammatory disease. Am J Pathol. 1993; 143: 3-9.
19. Sadick H, Riedel F, Naim R, et al. Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta1 as well as high ALK1 tissue expression. Haematologica. 2005; 90: 818-828.
20. Holderfield MT, Hughes CC,. Crosstalk between vascular endothelial growth factor, notch, and transforming growth factor-beta in vascular morphogenesis. Circ Res. 2008; 102: 637-652.
21. Cheifetz S, Bellón T, Calés C, et al. Endoglin is a component of the transforming growth factor-β receptor system in human endothelial cells. J Biol Chem. 1992; 267: 19027-19030.
22. Toporsian M, Gros R, Kabir MG, et al. A role for endoglin in coupling eNOS activity and regulating vascular tone revealed in hereditary hemorrhagic telangiectasia. Circ Res. 2005; 96: 684-692.
23. Abdalla SA, Letarte M,. Hereditary haemorrhagic telangiectasia: current views on genetics and mechanisms of disease. J Med Genet. 2006; 43: 97-110.
24. Bourdeau A, Dumont DJ, Letarte M,. A murine model of hereditary hemorrhagic telangiectasia. J Clin Invest. 1999; 104: 1343-1351.
25. Bourdeau A, Faughnan ME, McDonald ML, et al. Potential role of modifier genes influencing transforming growth factor-beta1 levels in the development of vascular defects in endoglin heterozygous mice with hereditary hemorrhagic telangiectasia. Am J Pathol. 2001; 158: 2011-2020.
26. Ohkawara T, Nishihira J, Takeda H, et al. Geranylgeranylacetone protects mice from dextran sulfate sodium-induced colitis. Scand J Gastroenterol. 2005; 40: 1049-1057.
27. Dieleman LA, Palmen MJ, Akol H, et al. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol. 1998; 114: 385-391.
28. Venkatesha S, Toporsian M, Lam C, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006; 12: 642-649.
29. Khazaei M, Nematbakhsh M,. Coronary vascular and aortic endothelial permeability during estrogen therapy: a study in DOCA-salt hypertensive ovariectomized rats. Physiol Res. 2004; 53: 609-614.
30. Toporsian M, Govindaraju K, Nagi M, et al. Downregulation of endothelial nitric oxide synthase in rat aorta after prolonged hypoxia in vivo. Circ Res. 2000; 86: 671-675.
31. Okayasu I, Hatakeyama S, Yamada M, et al. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology. 1990; 98: 694-702.
32. Melgar S, Karlsson A, Michaelsson E,. Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation. Am J Physiol Gastrointest Liver Physiol. 2005; 288: G1328-1338.
33. Ghia JE, Blennerhassett P, Deng Y, et al. Reactivation of inflammatory bowel disease in a mouse model of depression. Gastroenterology. 2009; 136: 2280-2288 e2281-2284.
34. Peng XD, Wu XH, Chen LJ, et al. Inhibition of phosphoinositide 3-kinase ameliorates dextran sodium sulfate-induced colitis in mice. J Pharmacol Exp Ther. 2010; 332: 46-56.
35. Chidlow JH, Jr., Shukla D, Grisham MB, et al. Pathogenic angiogenesis in IBD and experimental colitis: new ideas and therapeutic avenues. Am J Physiol Gastrointest Liver Physiol. 2007; 293: G5-G18.
36. Danese S, Sans M, de la Motte C, et al. Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology. 2006; 130: 2060-2073.
37. Hatoum OA, Heidemann J, Binion DG,. The intestinal microvasculature as a therapeutic target in inflammatory bowel disease. Ann N Y Acad Sci. 2006; 1072: 78-97.
38. Sadick H, Naim R, Gossler U, et al. Angiogenesis in hereditary hemorrhagic telangiectasia: VEGF165 plasma concentration in correlation to the VEGF expression and microvessel density. Int J Mol Med. 2005; 15: 15-19.
39. Shao ES, Lin L, Yao Y, et al. Expression of vascular endothelial growth factor is coordinately regulated by the activin-like kinase receptors 1 and 5 in endothelial cells. Blood. 2009; 114: 2197-2206.
40. Dor Y, Djonov V, Abramovitch R, et al. Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J. 2002; 21: 1939-1947.
41. Xu B, Wu YQ, Huey M, et al. Vascular endothelial growth factor induces abnormal microvasculature in the endoglin heterozygous mouse brain. J Cereb Blood Flow Metab. 2004; 24: 237-244.
42. Hao Q, Su H, Marchuk DA, et al. Increased tissue perfusion promotes capillary dysplasia in the ALK1-deficient mouse brain following VEGF stimulation. Am J Physiol Heart Circ Physiol. 2008; 295: H2250-2256.
43. Ganta VC, Cromer W, Mills GL, et al. Angiopoietin-2 in experimental colitis. Inflamm Bowel Dis. 2009 [Epub ahead of print].
44. Nagy JA, Benjamin L, Zeng H, et al. Vascular permeability, vascular hyperpermeability and angiogenesis. Angiogenesis. 2008; 11: 109-119.
45. Dvorak HF, Nagy JA, Feng D, et al. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol. 1999; 237: 97-132.
46. Pettersson A, Nagy JA, Brown LF, et al. Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor. Lab Invest. 2000; 80: 99-115.
47. Feng D, Nagy JA, Dvorak AM, et al. Different pathways of macromolecule extravasation from hyperpermeable tumor vessels. Microvasc Res. 2000; 59: 24-37.